- Northwest Biotherapeutics (NWBO -0.2%) takes umbrage with TheStreet's Adam Feuerstein in response to his May 27 article asserting that the company's DCVax isn't working. He says the company's stated maximum tumor shrinkage of 28% in some Phase 1 trial patients falls short of the globally-accepted RECIST standard of at least a 30% reduction to qualify as a valid partial response.
- Northwest retorts in a press release today that there are numerous established measures of patient responses to therapies. It makes no claims regarding the RECIST criteria, but acknowledges the 30% partial response metric. It also cites the standard of "Stable Disease" for tumor shrinkage up to 28%. CEO Linda Powers says, "Feuerstein's so-called analyses consist of false statements, serious misrepresentations and personal attacks and smears."
- The rhubarb began in March.